JY
ORMP icon

Jeff Yass’s Oramed Pharmaceuticals ORMP Stock Holding History

Jeff Yass’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,000
Closed -$38.7K – 13191
2024
Q4 		$38.7K Buy
+16,000
New +$38K ﹤0.01% 11772
2023
Q1 		– Sell
-153,600
Closed -$1.85M – 13221
2022
Q4 		$1.85M Buy
153,600
+88,100
+135% +$685K ﹤0.01% 4858
2022
Q3 		$424K Buy
65,500
+36,100
+123% +$292K ﹤0.01% 8910
2022
Q2 		$135K Sell
29,400
-34,200
-54% -$183K ﹤0.01% 11158
2022
Q1 		$550K Sell
63,600
-34,100
-35% -$349K ﹤0.01% 8735
2021
Q4 		$1.4M Buy
97,700
+21,100
+28% +$441K ﹤0.01% 6398
2021
Q3 		$1.68M Buy
76,600
+59,000
+335% +$1M ﹤0.01% 6207
2021
Q2 		$235K Sell
17,600
-7,000
-28% -$80.1K ﹤0.01% 11256
2021
Q1 		$250K Buy
+24,600
New +$202K ﹤0.01% 10984
2020
Q1 		– Sell
-15,400
Closed -$79K – 10700
2019
Q4 		$79K Buy
+15,400
New +$57.7K ﹤0.01% 9221
2016
Q3 		– Sell
-11,700
Closed -$98K – 8855
2016
Q2 		$98K Sell
11,700
-8,600
-42% -$73.3K ﹤0.01% 8032
2016
Q1 		$135K Buy
20,300
+2,400
+13% +$16.1K ﹤0.01% 8278
2015
Q4 		$153K Buy
+17,900
New +$136K ﹤0.01% 8641
2015
Q3 		– Sell
-19,500
Closed -$111K – 10006
2015
Q2 		$111K Buy
19,500
+5,700
+41% +$39K ﹤0.01% 9634
2015
Q1 		$88K Sell
13,800
-1,600
-10% -$7.73K ﹤0.01% 9007
2014
Q4 		$70K Sell
15,400
-12,300
-44% -$80.9K ﹤0.01% 9293
2014
Q3 		$223K Sell
27,700
-24,800
-47% -$220K ﹤0.01% 8496
2014
Q2 		$505K Buy
+52,500
New +$536K ﹤0.01% 7459

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's ORMP Position: Q2 2026 in Review

Jeff Yass reduced its Oramed Pharmaceuticals (ORMP) stake by 84% in Q2 2026, selling an estimated $453K and leaving 22,300 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #12454.

Jeff Yass first reported a position in ORMP in Q1 2014 and has held it in 31 quarters since. The position peaked at $2.23M in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Jeff Yass held 22,300 shares of Oramed Pharmaceuticals worth $107K as of Q2 2026.
  • Jeff Yass sold 113,918 Oramed Pharmaceuticals shares in Q2 2026, an estimated $453K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12454 holding.
  • Jeff Yass first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 31 quarters since.
  • Jeff Yass's Oramed Pharmaceuticals position peaked at $2.23M in Q4 2022.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.